Savara Inc Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Savara Inc (SVRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 101.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-08-11
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-06-30 was 101.00K shares, a 51.90% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-12-31 was 25.00K shares.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 545.00K shares, a 431.71% increase from fiscal 2024.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 102.50K shares.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2022 was 270.45K shares, a 527.14% increase from fiscal 2021.
- Savara Inc share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2021 was 43.13K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 101.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 101.00K shares 10-Q · filed 2026-08-11 | 126.00K shares derived: sum of 3 quarters · filed 2026-08-11 | 126.00K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-12 | 25.00K shares derived: sum of 2 quarters · filed 2026-05-12 | 25.00K shares derived: sum of 3 quarters · filed 2026-05-12 | 235.00K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 25.00K shares derived: sum of 2 quarters · filed 2026-03-13 | 235.00K shares derived: sum of 3 quarters · filed 2026-03-13 | 545.00K shares 10-K · filed 2026-03-13 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 210.00K shares derived: sum of 2 quarters · filed 2025-11-12 | 520.00K shares 10-Q · filed 2025-11-12 | 520.00K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 210.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 520.00K shares 10-Q · filed 2025-08-13 | 520.00K shares derived: sum of 3 quarters · filed 2025-08-13 | 555.00K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 310.00K shares 10-Q · filed 2025-05-13 | 310.00K shares derived: sum of 2 quarters · filed 2025-05-13 | 345.00K shares derived: sum of 3 quarters · filed 2025-05-13 | 412.50K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 35.00K shares derived: sum of 2 quarters · filed 2025-03-27 | 102.50K shares derived: sum of 3 quarters · filed 2025-03-27 | 102.50K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 35.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 102.50K shares derived: sum of 2 quarters · filed 2024-11-12 | 102.50K shares 10-Q · filed 2024-11-12 | |
| 2024-06-30 | 67.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 67.50K shares 10-Q · filed 2024-08-12 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 468.00 shares derived: sum of 2 quarters · filed 2023-11-09 | 1.02K shares 10-Q · filed 2023-11-09 | 21.47K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 468.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.02K shares 10-Q · filed 2023-08-10 | 21.47K shares derived: sum of 3 quarters · filed 2023-08-10 | 146.47K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 551.00 shares 10-Q · filed 2023-05-15 | 21.00K shares derived: sum of 2 quarters · filed 2023-05-15 | 146.00K shares derived: sum of 3 quarters · filed 2023-05-15 | 271.00K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 20.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 145.45K shares derived: sum of 2 quarters · filed 2023-03-30 | 270.45K shares derived: sum of 3 quarters · filed 2023-03-30 | 270.45K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 125.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 250.00K shares derived: sum of 2 quarters · filed 2022-11-10 | 250.00K shares 10-Q · filed 2022-11-10 | 250.00K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 125.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 125.00K shares 10-Q · filed 2022-08-11 | 125.00K shares derived: sum of 3 quarters · filed 2022-08-11 | 125.00K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-11 | 0.00 shares derived: sum of 2 quarters · filed 2022-05-11 | 0.00 shares derived: sum of 3 quarters · filed 2022-05-11 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2022-03-30 | 43.13K shares 10-K · filed 2022-03-30 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 43.13K shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 43.13K shares 10-Q · filed 2021-08-12 | |||
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-12 | |||
| 2017-03-31 | 227.00 shares 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |